CG Oncology IncNASDAQ:CGON
- LAST PRICE41.0000
- TODAY'S CHANGE (%)4.8000 (13.2597%)
- Bid / Lots38.1000/ 2
- Ask / Lots47.0000/ 1
- Open / Previous Close36.9300 / 36.2000
- Day Range
- 52 Week Range
- Volume819,590
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CGON |
|---|---|---|
| 09:32 ET | 1091 | 36.93 |
| 09:34 ET | 100 | 36.89 |
| 09:36 ET | 300 | 36.495 |
| 09:38 ET | 800 | 37 |
| 09:39 ET | 100 | 37.14 |
| 09:41 ET | 200 | 37.04 |
| 09:43 ET | 3807 | 36.8 |
| 09:45 ET | 1805 | 36.89 |
| 09:48 ET | 2700 | 37.08 |
| 09:50 ET | 100 | 37.085 |
| 09:52 ET | 1500 | 37.37 |
| 09:56 ET | 400 | 37.37 |
| 09:57 ET | 1400 | 37.31 |
| 10:03 ET | 705 | 37.2 |
| 10:06 ET | 800 | 37.23 |
| 10:08 ET | 200 | 37.12 |
| 10:10 ET | 300 | 37.27 |
| 10:12 ET | 300 | 37.275 |
| 10:14 ET | 100 | 37.29 |
| 10:15 ET | 300 | 37.26 |
| 10:17 ET | 100 | 37.3 |
| 10:19 ET | 100 | 37.265 |
| 10:21 ET | 300 | 37.315 |
| 10:24 ET | 7138 | 37.435 |
| 10:26 ET | 100 | 37.425 |
| 10:28 ET | 100 | 37.64 |
| 10:30 ET | 200 | 37.52 |
| 10:32 ET | 300 | 37.74 |
| 10:33 ET | 200 | 37.76 |
| 10:35 ET | 200 | 37.87 |
| 10:37 ET | 200 | 37.84 |
| 10:39 ET | 225 | 37.8117 |
| 10:42 ET | 1100 | 37.835 |
| 10:44 ET | 200 | 37.62 |
| 10:48 ET | 500 | 37.6 |
| 10:51 ET | 636 | 37.5 |
| 10:53 ET | 545 | 37.51 |
| 10:55 ET | 100 | 37.63 |
| 11:00 ET | 599 | 37.65 |
| 11:04 ET | 854 | 37.715 |
| 11:06 ET | 100 | 37.64 |
| 11:09 ET | 100 | 37.675 |
| 11:11 ET | 100 | 37.77 |
| 11:13 ET | 1600 | 37.81 |
| 11:15 ET | 100 | 37.86 |
| 11:18 ET | 100 | 37.81 |
| 11:20 ET | 200 | 37.75 |
| 11:22 ET | 900 | 37.77 |
| 11:26 ET | 1100 | 37.8 |
| 11:27 ET | 400 | 37.725 |
| 11:29 ET | 300 | 37.725 |
| 11:31 ET | 1337 | 37.94 |
| 11:33 ET | 100 | 38.05 |
| 11:36 ET | 300 | 37.98 |
| 11:38 ET | 353 | 37.97 |
| 11:44 ET | 1300 | 38.16 |
| 11:45 ET | 1300 | 38.305 |
| 11:49 ET | 300 | 38.455 |
| 11:51 ET | 500 | 38.48 |
| 11:56 ET | 100 | 38.5 |
| 11:58 ET | 100 | 38.485 |
| 12:00 ET | 100 | 38.5 |
| 12:02 ET | 300 | 38.525 |
| 12:03 ET | 100 | 38.51 |
| 12:07 ET | 200 | 38.51 |
| 12:12 ET | 200 | 38.58 |
| 12:16 ET | 100 | 38.545 |
| 12:18 ET | 1121 | 38.84 |
| 12:21 ET | 300 | 38.88 |
| 12:23 ET | 800 | 38.94 |
| 12:25 ET | 982 | 39.09 |
| 12:27 ET | 100 | 39.075 |
| 12:32 ET | 200 | 39.133 |
| 12:34 ET | 589 | 39.24 |
| 12:39 ET | 700 | 39.43 |
| 12:43 ET | 1412 | 39.645 |
| 12:45 ET | 200 | 39.73 |
| 12:48 ET | 1000 | 39.71 |
| 12:50 ET | 100 | 39.765 |
| 12:52 ET | 400 | 39.88 |
| 12:54 ET | 4957 | 40.24 |
| 12:56 ET | 100 | 40.34 |
| 12:57 ET | 1693 | 40.4 |
| 01:01 ET | 300 | 40.509 |
| 01:03 ET | 100 | 40.59 |
| 01:06 ET | 3120 | 40.44 |
| 01:08 ET | 300 | 40.58 |
| 01:10 ET | 200 | 40.515 |
| 01:12 ET | 1700 | 40.4 |
| 01:14 ET | 5595 | 40.09 |
| 01:15 ET | 2687 | 40.215 |
| 01:17 ET | 10000 | 40.175 |
| 01:19 ET | 3821 | 40.07 |
| 01:21 ET | 2065 | 40.11 |
| 01:24 ET | 300 | 40.16 |
| 01:26 ET | 800 | 40.145 |
| 01:28 ET | 200 | 40.16 |
| 01:30 ET | 300 | 40.135 |
| 01:32 ET | 3400 | 40.46 |
| 01:33 ET | 200 | 40.425 |
| 01:35 ET | 400 | 40.31 |
| 01:44 ET | 200 | 40.26 |
| 01:46 ET | 2224 | 40.33 |
| 01:48 ET | 4821 | 39.96 |
| 01:51 ET | 25000 | 40.07 |
| 01:53 ET | 900 | 40.175 |
| 01:55 ET | 16824 | 40.665 |
| 01:57 ET | 4937 | 40.845 |
| 02:00 ET | 8873 | 40.77 |
| 02:02 ET | 25534 | 40.3 |
| 02:04 ET | 100 | 40.07 |
| 02:06 ET | 3500 | 40.15 |
| 02:08 ET | 600 | 40.07 |
| 02:09 ET | 900 | 40 |
| 02:11 ET | 300 | 40.02 |
| 02:13 ET | 531 | 40.02 |
| 02:15 ET | 200 | 39.915 |
| 02:18 ET | 400 | 39.92 |
| 02:20 ET | 1702 | 40.3 |
| 02:22 ET | 100 | 40.255 |
| 02:24 ET | 200 | 40.24 |
| 02:26 ET | 1100 | 40.43 |
| 02:27 ET | 100 | 40.61 |
| 02:29 ET | 100 | 40.56 |
| 02:31 ET | 200 | 40.56 |
| 02:33 ET | 613 | 40.4 |
| 02:36 ET | 300 | 40.46 |
| 02:38 ET | 600 | 40.6 |
| 02:42 ET | 100 | 40.615 |
| 02:44 ET | 200 | 40.79 |
| 02:45 ET | 200 | 40.78 |
| 02:47 ET | 4042 | 40.29 |
| 02:49 ET | 1100 | 39.995 |
| 02:51 ET | 9163 | 40.12 |
| 02:56 ET | 300 | 40.34 |
| 03:00 ET | 7832 | 40.54 |
| 03:02 ET | 591 | 40.64 |
| 03:03 ET | 200 | 40.55 |
| 03:05 ET | 100 | 40.55 |
| 03:07 ET | 500 | 40.47 |
| 03:09 ET | 200 | 40.53 |
| 03:12 ET | 1300 | 40.56 |
| 03:14 ET | 1800 | 40.765 |
| 03:16 ET | 300 | 40.97 |
| 03:18 ET | 474 | 40.885 |
| 03:20 ET | 3358 | 40.865 |
| 03:21 ET | 201335 | 40.51 |
| 03:23 ET | 21663 | 40.45 |
| 03:25 ET | 400 | 40.455 |
| 03:27 ET | 61260 | 40.45 |
| 03:30 ET | 1400 | 39.9 |
| 03:32 ET | 5599 | 40.5 |
| 03:34 ET | 4567 | 40.555 |
| 03:36 ET | 900 | 40.61 |
| 03:38 ET | 400 | 40.67 |
| 03:39 ET | 200 | 40.655 |
| 03:41 ET | 700 | 40.57 |
| 03:43 ET | 4457 | 40.7 |
| 03:45 ET | 1200 | 40.85 |
| 03:48 ET | 27781 | 40.93 |
| 03:50 ET | 2800 | 41.105 |
| 03:52 ET | 1200 | 41.07 |
| 03:54 ET | 5267 | 41.115 |
| 03:56 ET | 59602 | 40.7 |
| 03:57 ET | 12894 | 41.02 |
| 03:59 ET | 18263 | 41 |
Apr 26, 2024
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024, from 8:00AM ET on Friday Apr 26, 2024 by Dow Jones
8:00AM ET on Friday Apr 26, 2024 by Dow Jones
Apr 24, 2024
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024, from 10:00AM ET on Wednesday Apr 24, 2024 by Dow Jones
10:00AM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 4, 2024
DJ CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co., from 6:21AM ET on Thursday Apr 04, 2024 by Dow Jones
6:21AM ET on Thursday Apr 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CG Oncology Inc | 2.7B | -38.4x | --- |
MoonLake Immunotherapeutics | 2.7B | -55.7x | --- |
Summit Therapeutics Inc | 2.7B | -2.5x | --- |
Apogee Therapeutics Inc | 2.7B | -27.1x | --- |
Xenon Pharmaceuticals Inc | 3.1B | -14.8x | --- |
Janux Therapeutics Inc | 2.4B | -35.3x | --- |
Company Information
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
Contact Information
- Headquarters
- 400 Spectrum Center Drive, Suite 2040IRVINE, CA, United States 92618
- Phone
- 949-288-6298
- Fax
- 302-531-3150
Executives
- Chairman of the Board, Chief Executive Officer
- Arthur Kuan
- President, Chief Operating Officer
- Ambaw Bellete
- Chief Financial Officer
- Stephen Dipalma
- Chief Medical Officer
- Vijay Kasturi
- Lead Independent Director
- Leonard Post
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
|---|---|
Revenue (TTM) | $204.0K |
Shares Outstanding | 66.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.07 |
Book Value | $2.91 |
P/E Ratio | -38.4x |
Price/Sales (TTM) | 13,392.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -27,180.88% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
